Streptokinase

Summary

Streptokinase (CHEMBL2108147) is an approved enzyme (ATC B01AD01); indicated across 9 conditions including thrombotic disease and myocardial infarction.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• ATC class: B01AD01 (+1 more)
• Indications: 9 conditions
• Clinical trials: 16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108147
Name	Streptokinase
Type	Enzyme
Max phase	4
ATC	B01AD01, B06AA55

Also known as: Estreptoquinasa, Kabikinase, Streptase, Streptokinase, Streptokinase c, STREPTOKINASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
thrombotic disease	4	MONDO:0000831	HP:0004419
myocardial infarction	3	MONDO:0005068	EFO:0000612
myocardial ischemia	3	MONDO:0024644	EFO:1001375
acute myocardial infarction	3	MONDO:0004781	EFO:0008583
coronary artery disorder	3	MONDO:0005010	EFO:0001645
heart disorder	3	MONDO:0005267	EFO:0003777
acute pancreatitis	2	MONDO:0006515	EFO:1000652

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE3	6
Not specified	5
PHASE4	3
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00627809	PHASE4	COMPLETED	Effect of Adjunctive Intracoronary Streptokinase on Late Term Left Ventricular Infarct Size and Volumes in Patients With Acute Myocardial Infarction
NCT00968929	PHASE4	COMPLETED	Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)
NCT03172052	PHASE4	UNKNOWN	Evaluating Different Modalities for Pleural Adhesiolysis at Assuit University Hospital
NCT00000503	PHASE3	COMPLETED	Randomized Clinical Trial of Non-Surgical Reperfusion of the Coronary Arteries
NCT00000507	PHASE3	COMPLETED	Intravenous Streptokinase in Acute Myocardial Infarction
NCT00232622	PHASE3	COMPLETED	A Study Comparing a New Dosing Regimen of Clot-dissolving Drug for Mechanical Heart Valves Which Show Clots
NCT01305226	PHASE3	COMPLETED	A Trial Using Double-Bolus THR-100 Versus Streptokinase
NCT01977118	PHASE2/PHASE3	COMPLETED	Use of Streptokinase for Enhancement of Percutaneous Drainage of Pancreatic Necrosis
NCT02182011	PHASE3	COMPLETED	A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)
NCT03465085	PHASE3	COMPLETED	Streptokinase Versus Unfractionated Heparin Nebulization in Severe ARDS
NCT02150785	PHASE2	WITHDRAWN	Asia Africa Streptokinase Trial
NCT06545864	Not specified	NOT_YET_RECRUITING	Systemic Thrombolysis Versus Catheter Directed Management for Acute Intermediate-high Pulmonary Embolism
NCT01451320	Not specified	COMPLETED	Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis
NCT02893280	Not specified	WITHDRAWN	Acute Coronary Syndrome Sri Lanka Audit Project
NCT03595085	Not specified	UNKNOWN	Catheter Directed Interventions in Pulmonary Embolism
NCT07360717	Not specified	COMPLETED	To Compare the Efficacy & Safety of Ultra-Slow (24 hr) Low Dose (25 mg) Infusion of Alteplase Over Slow (24hr) Infusion of Streptokinase in Mechanical Prosthetic Valve Thrombosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).